🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05719766
Starting soon Not applicable

Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients

NCT05719766 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2023-04-01
Last updated
2023-02-21

Condition(s) studied

Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis

Investigational drug(s) / intervention(s)

education ,psycological support and social support

education ,psycological support and social support: we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire

Study summary

This study aims to prospectively explore the effect of incentive-integrated E-IBD (electronic inflammatory bowel disease) chronic disease management model on the improvement of IBD quality of life, and provide a more effective chronic disease management model for improving the quality of life and social participation of IBD patients.The investigators firstly identify the IBD patients in need of empowerment disease activities through the questionnaire .Then, the investigators feedback the patients' education content according to their needs found.Based on the social support network of patient organization and the medical support network of tertiary medical institutions, the investigators complete the empowerment process of IBD patients' self-management initiative and self-management ability, through the internet. Finally ,the investigators evaluate the quality of life(QoL), social participation,disease self-management level via questionnaire . The primary outcome is the improvement of QoL score after three months' intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * 1.Clinically diagnosed IBD patients,according to the criteria of the Inflammatory Bowel Group of the Gastroenterology Branch of the Chinese Medical Association in 2018; * 2.Aged 18 to 75 years old; * 3.Understand and comply with the requirements of the program and sign informed consent. * 4.Identified as need intervention according to the patient identification questionnaire screening; * 5.Patients with the ability to complete all course training and/or follow-up work; * 6.Enrolled at least one year ahead of end of this study(for garantee of enough folllow-up time). Exclusion Criteria: * 1.Unable or unwilling to sign the consent form, or unable to follow the research procedure; * 2.Patients who have had a stoma or ileorectal anastomosis (partial scales are not available); * 3.Patients who do not complete training on time or do not complete follow-up assessments in their entirety; * 4.Patients with other malignancies or life-threatening complications; * 5.Pregnancy or lactation; * 6.Patients whose remaining follow-up time less than one year before the end of this study.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou China
Department of Gastroenterology, Huzhou Central Hospital Huzhou China
Department of Gastroenterology, Ruijin Hospital Shanghai China
Department of Gastroenterology, Shaoxing Central Hospital Shaoxing China

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05719766 on ClinicalTrials.gov ↗ ← All trials in China